key: cord-1022169-7iakmerk
authors: Bard, Jennifer Dien; Babady, N Esther
title: The Successes and Challenges of SARS-CoV-2 Molecular Testing in the United States
date: 2022-03-08
journal: Clin Lab Med
DOI: 10.1016/j.cll.2022.02.007
sha: 1a2cbaa6fd6209e08edd39e1964a04ba9a50c865
doc_id: 1022169
cord_uid: 7iakmerk

nan

Organization (WHO), which had a sensitivity of 26% and specificity of 96% (2). Fast forward 17 36 years and scientists in China reported the identification of a novel coronavirus, eventually called 37 SARS-CoV-2, on January 9 th , 2020, as the cause of the coronavirus disease 2019 syndrome. The identification of SARS-CoV-2 was less than two weeks from the initial report 39 made to the WHO and the whole genome of the virus was made publicly available the next day 40 diseases (12) . Two assays, the Bio-Rad SARS-CoV-2 ddPCR test (Bio-Rad Laboratories, Inc.) 98 and FastPlex Triplex SARS-CoV-2 (PreciGenome LLC) have now received FDA EUA status. 99 While there are currently no peer-reviewed publications on these specific assays, several 100 studies have reported increased sensitivity of ddPCR assays compared to quantitative PCR 101 (qPCR), showing its potential provide a valid alternative (13, 14) . Furthermore, the ability of 102 ddPCR to provide absolute quantification could fill an existing gap related to the inability to 103 perform viral load measurement for disease monitoring and infection control purposes. For the 104 time being, currently authorized ddPCR platforms remain qualitative only and turn-around time 105

to results are longer than for most qPCR instruments. Digital PCR instruments are also not as 106 widely available in clinical microbiology laboratories as PCR thermocyclers. 107 One of the major success of molecular testing during the pandemic, was the availability of 108 rapid, point-of-care molecular tests. The ID Now COVID-19 test (Abbott Diagnostics Inc., 109 Scarborough, ME) is an isothermal NAAT designed for testing on the ID Now platform, which is 110 cleared for use at the point of care and provides results in as little as 5 minutes. Early studies 111 analytical performance compared to real-time RT-PCR tests, but given that amplification is 124 isothermal, it is expected that sensitivity would be lower (though higher than for rapid antigen 125 tests). Data from the manufacturer reports the limit of detection (LOD) as 800 to 1,300 126 copies/mL. Therefore, a negative test in a symptomatic patient should be confirmed with a PCR 127 test, which is similar to algorithms that rely on antigen testing. 128

Not only was molecular testing critical for diagnosing symptomatic individuals with 130 COVID-19, it played a key role in keeping places such as healthcare settings and schools as 131 safe as possible through surveillance testing of asymptomatic individuals. The ability to maintain 132 highly sensitive and accurate testing at a large scale was largely due to the inherent adaptability 133 of molecular testing. The ability to modify nearly any aspect of the pre-analytic and analytic 134 components of a PCR testing protocol, from collection devices to amplification techniques, 135 allows it to be tailored to the specific needs of the setting in which it is deployed, while 136 optimizing its robustness to shortages in supplies and labor. 137 increase in testing needs early in the pandemic resulted in a sudden and dramatic shortage in 149 swabs that was mitigated either by the foresight to horde tens of thousands of swabs for internal 150 use, the acquisition of swabs from less well-known sources or to explore the use of 3D printed 151 swabs. The rapid adoption of 3D printing is a prime example of the creativity and the 152 perseverance of laboratorians to dodge interruptions in clinical service. The performance of 153 these swabs was found to be equivalent to flocked swabs, paving the way for a stable supply of 154 this critical resource (22). 155

Alternative sample types 157 Molecular testing is technically agnostic to sample type. However, in order for results to 158 be meaningful for a provider, the body site must be considered clinically relevant and the 159 sample type must have undergone sufficient validation. Whilst the collection of nasopharyngeal 160 swabs (NPS) is considered the gold standard specimen collection method for SARS-CoV-2, 161 several challenges have prompted commercial partners and CLIA certified laboratories to 162 explore alternate specimen sources that does not require specialized collection devices (e.g. 163 nasopharyngeal swabs and viral transport media). These challenges include the often painful or 164 uncomfortable collection process, the need for personal protective equipment (PPE) for 165 healthcare workers performing testing and, as mentioned above, supply chain shortages (23). 166

Thus, considerable efforts were made to explore and implement alternate clinical specimen 167 types for the molecular detection of SARS-CoV-2. Currently, the Infectious Diseases Society of 168 America (IDSA) and the Centers for Disease Control and Prevention (CDC) have approved 169 other specimen types for SARS-CoV-2 testing including oropharyngeal swabs (OPS), mid-170 turbinate swabs (MTS), anterior nares swabs (ANS), saliva and lower respiratory specimens. and universities. Much attention has been given to saliva due to the ease of collection, and the 175 lack of need for a swab, buffer solution and even PPE (24). The sensitivity of molecular tests on 176 saliva samples varied widely depending on the assays but performance as high as 95% has 177 been reported (24-26), when compared to PCR testing on nasopharyngeal swabs and several 178 assays have received FDA EUA for detection of SARS-CoV-2 (19). As data emerged on the 179 utility of alternative samples for SARS-CoV-2 detection, saliva samples as well as nasal and 180 mid-turbinate swabs samples were preferred over the use of the more established OPS (27). 181

The success of molecular testing on saliva and other non-nasopharyngeal sample types will 182 likely have a major impact on the diagnosis and management of many other infectious diseases 183 post-pandemic. 184 185

Molecular testing approaches for SARS-CoV-2 have the flexibility to improve the speed 187 and throughput of testing by bypassing external extraction steps and through specimen pooling 188 algorithms, respectively. Neither approach is considered novel and they have been an integral 189 part of laboratory medicine for many years prior to the COVID-19 pandemic. For example, many 190 multiplexed syndromic testing panels for respiratory infections and gastroenteritis are built as 191 sample-to-answer instruments that integrate nucleic acid extraction with amplification and signal 192 detection. Results are typically available within one hour (28). The ability to modify or eliminate 193 steps is an important feature of any molecular test, and particularly for PCR-based testing, as it 194

can significantly reduce the time to result without affecting analytic sensitivity (18, 29). 195 With regards to specimen pooling, combining multiple specimens prior to nucleic acid 196 extraction can be easily accommodated from the analytical perspective as the extraction 197 process itself remains the same. Specimen pooling algorithms have been successfully deployed 198 for other infectious diseases such as HIV (30), with minimal effects on sensitivity. Pooling studies for SARS-CoV-2 using PCR-based methods and other molecular approaches like 200 CRISPR have found that sensitivity can be maintained when up to 5 specimens are pooled, with 201 decreases thereafter as the number of specimens included in the pool increases (31). Pooling 202 can be an effective approach for asymptomatic surveillance in the community to facilitate early 203 detection of COVID-19, provided that disease prevalence remains low (32). 204 205

The availability of next generation sequencing (NGS) to investigate the initial Wuhan 207 clusters and produce the first complete genome of SARS-CoV-2 within days was crucial to 208 diagnostic assay development and to the molecular characterization of this novel virus (4). that are predicted or known to affect transmissibility, disease severity, immunity, diagnostic 238 accuracy or therapeutic success were considered VOIs. VOCs were VOIs for which there was 239 actual evidence of increased transmissibility or increased virulence, decreased protection from 240 vaccination or previous infection, diagnostic failures or reduced effectiveness of therapeutics 241 (41, 42). As VOIs and VOCs started to emerge in many countries, a naming scheme that used 242 the Greek alphabet was developed by WHO experts to facilitate discussions by non-scientific 243 audiences and to prevent the stigma associated with naming VOIs/VOCs after the countries in 244 which they were first identified. Beyond global surveillance testing to monitor emerging SARS-245

CoV-2 lineages, NGS performed in clinical laboratories provided data that supported local 246 hospital outbreak investigations and transmission events or local efforts to monitor and establish 247 links between emerging variants and vaccines breakthroughs (43-46). particularly as traditional NAAT-based diagnostic testing required constant human, material and 250 financial support throughout the pandemic. Furthermore, for most clinical virology and 251 microbiology laboratories, NGS was not a technique used routinely and thus to perform 252 surveillance in-house required a significant amount of new investment not only in NGS 253 instrumentation but also in technologists with strong skillsets for molecular techniques as well as 254 in staff with the ability to use bioinformatic tools for data analysis of SARS-CoV-2 sequences. 255

The complexity of NGS for routine surveillance of SARS-CoV-2 prompted the development of 256 targeted PCR to identify specific VOC/VOI through detection of known key mutations (47, 48) . 257

This approach took advantages of existing skills and infrastructures in clinical laboratories to 258 rapidly identify VOC/VOI. However, as successive waves of the pandemic rose and fell and the 259 frequencies of VOC/VOI changed frequently, the utility of targeted approaches became limited. 260 NGS has become the method of choice for surveillance of SARS-CoV-2 as it is agnostic to 261 variants. However, the use of NGS comes with its own set of challenges that include the 262 introduction of artifacts into output datasets by the methods (tiled amplicons vs metagenomics), 263 and platforms (e.g. long reads vs short reads) used. It is essential that the chosen bioinformatic 264 pipelines are validated to reduce the risk of bias in data interpretation and standardization (49). 265

Despite the increased complexity of NGS, there is increasing interest and a potential role in 266 offering SARS-CoV-2 genotyping as a clinical test as it may contribute to the selection or 267 avoidance of some monoclonal antibody or antiviral therapies (50). 268

The success of NGS during the SARS-CoV-2 pandemic was also due in part to the increase 269 in data sharing globally, primarily through the Global Initiative on Sharing All Influenza Data 270 (GISAID) initiative, which pivoted early in the pandemic to developing and providing tools that 271 enabled validation and free data sharing of SARS-CoV-2 genomes as well as for visualization 272 and real-time tracking (51). As of February 2022, more than 7,700,000 SARS-CoV-2 genomes 273 have been submitted to GISAID. While submissions are heavily biased towards laboratories 274 from high and middle-income countries, the free access and the extent of sharing of genomic 275 data has been unprecedented and has allowed for truly global surveillance of viral evolution. In 276 addition to GISAID and other data repository tools (e.g. NCBI GenBank), open software 277 platforms such as Nextstrain and Phylogenetic Assignment of Named Global Outbreak 278 Lineages (PANGOLIN) have facilitated the assignments of SARS-CoV-2 lineages, particularly 279 for laboratories with limited bioinformatics skills (52-55). 280

While the successes of molecular testing are worthy of celebration, we would be remiss to not 282 discuss their failures as well. Among them are the bureaucratic failures that severely delayed 283 the deployment of these vital tests at a critical moment early in the pandemic, global supply 284 chain bottlenecks, the inability of molecular tests to assess contagiousness, the paucity of 285 skilled laboratory scientists to meet testing demands and the lack of coordination with state and 286 federal public health laboratories. 287

While the CDC was able to achieve EUA status for their COVID-19 assay, most clinical 290 laboratories were not equipped to undertake the challenges associated with the complexity and 291 length of an FDA EUA submission. However, as cases of COVID-19 started to increase and 292 local transmission became evident, clinical laboratories and commercial entities appropriately 293 worked diligently to submit SARS-CoV-2 PCR tests for FDA review and approval. It became 294 immediately apparent that a significant challenge was the lack of a readily available gold 295 standard. Most laboratories at the beginning of the pandemic did not have access to samples 296 positive for SARS-CoV-2 or to well-characterized viral isolates. Furthermore, guidance was 297 J o u r n a l P r e -p r o o f samples, unless done in a Biosafety level 3 (BSL-3) laboratory, which is not available in many 299 clinical laboratories. These hurdles made establishing the performance characteristics of an 300 assay for this novel pathogen was quite challenging. Ultimately, on February 28 th , the FDA 301 issued a guidance for high-complexity laboratories and diagnostic manufacturers that provided a 302 simplified path to developing and obtaining EUA clearance for molecular diagnostic tests (56). 303

This guidance allowed laboratories to perform validation using viral RNA transcripts in the 304 absence of true clinical samples. Only after that point were both clinical laboratories and 305 commercial vendors able to move forward with developing molecular tests for SARS-CoV-2 306 RNA detection. In a matter of a few months, hundreds of SARS-CoV-2 molecular tests became 307 available. 308

One of the biggest challenges of the pandemic has undoubtedly been an inadequate supply 310 chain. Global travel and economic output came to a standstill in spring 2020 due to the strict 311 lockdowns occurring in many parts of the world simultaneously. At the same time, once 312 molecular tests were implemented in clinical laboratories, cases surged and with it, an 313 unexpected and unprecedented demand for rapid testing. This led to a significant mismatch 314 between supplies and demand for one of the most critical operations during the pandemic. The 315 challenges associated with limited supplies from sample collection devices (e.g. viral transport 316 media, nasopharyngeal swabs) to PCR reagents and instruments, created the need for 317 validating alternative molecular testing methods including RT-LAMP and transcription-mediated 318 amplification (TMA), and alternative sample types to minimize the need for specialized collection 319 kits or NAAT reagents. The first non-PCR NAATs to become commercially available were based 320 on isothermal amplification (e.g. ID Now COVID-19 Test, Abbott Inc.; Solana SARS-CoV-2 321 Assay, Quidel Inc.), with some having the added benefit of being able to use dry nasal swabs 322 than PCR. However, the performance of SARS-CoV-2 TMA assays (e.g. Aptima SARS-CoV-2 324 Assay, Hologic Inc.) showed similar sensitivity and specificity compared to PCRs, allowing for 325 further expansion of sensitive and accurate molecular tests during the pandemic (57). 326

The challenges associated with the supply chain and the costs of molecular tests led to 327 increasing delays in resulting turn-around times early in the pandemic. In response, non-328 molecular tests, primarily antigen-based, were developed to further expand testing and also fill 329 the gap for rapid, point-of-care testing. To date, over 25 antigen tests have received FDA EUA 330 status (58). The lower sensitivity of antigen assays, which do not employ amplification methods, 331 compared to molecular tests, was an anticipated challenge based on prior experience with rapid 332 influenza diagnostics tests (RIDTs). Numerous studies have now shown rapid antigen tests for 333 SARS-CoV-2 to have sensitivities as low as 35% in asymptomatic patients compared to PCRs, 334 though this improves to over 90% for samples with high viral loads (e.g. Ct values <30) (59-62). 335

Results of studies varied widely depending on the patient population tested (e.g. symptomatic 336 vs asymptomatic patients), the type of tests (e.g. lateral-flow assays vs high-throughput 337 chemiluminescence assays) and the timing of testing (e.g. early vs late infection). As such, 338 recommendations from the IDSA guidelines still support the use of molecular over antigen 339 testing whenever possible (63). The CDC guidelines similarly suggest an approach that takes 340 into consideration the patient population and the goal of testing to optimize the use of antigen 341 testing with recommendations to follow-up negative antigen tests with molecular testing in cases 342 of high suspicion of infection (64). 343

A major challenge for all types of diagnostic testing for SARS-CoV-2 is the inability to 345 discriminate between actively replicating virus and viral RNA fragments. This is particularly the 346 case for highly sensitive molecular testing assays. Early in pandemic the CDC recommended was not uncommon to detect viral RNA fragments for weeks or months after an individual has 349 completely recovered from COVID-19 (65). As such, the CDC modified their previous guidance 350 to remove testing for clearance and shift to a time-based strategy for safely returning back to 351 work or society (66). 352

Some have championed the use of viral cultures to determine active infection or 353 "infectivity" (67), which is unrealistic in practice as performing viral cultures is a time consuming 354 process that requires the availability of a BSL-3 laboratory. Due to low sensitivity, viral cultures 355 are also considered a suboptimal reference method compared to NAAT and the reason for why 356 the majority of clinical laboratories have abandoned its use for the detection of most viral 357 pathogens (68). 358

The use of rapid antigen tests (RAT) has also been proposed as a scalable and 359 relatively cheap means to detect "infectious" cases. The association between a positive antigen 360 test and contagiousness has been attributed to its lower sensitivitymeaning it should in theory 361 only detect samples with high viral load or low cycle threshold (Ct) values seen by PCR (69). 362

Unfortunately, data correlating Ct values and infectivity is lacking and the widespread use of 363 RAT has its own unique challenges. Additional discussion on the strengths and weaknesses of 364 RAT for SARS-CoV-2 is covered in a separate chapter in this issue. 365

Lastly, a molecular approach that has been proposed to identify actively replicating virus 366 compared to "dead" virus is the detection of minus-strand SARS-CoV-2 RNA (70) or 367 subgenomic RNA (71). These molecular testing approaches are tools that may assist in the 368 determination of infectiousness in certain clinical context such as in immunocompromised 369 patients with prolonged shedding (72) and could inform isolation strategies in a hospital setting 370 (70). However, conflicting data have been reported for the role of subgenomic RNA as a Limited molecular testing capability and shortage of highly skilled molecular 375

technologists 376

The lack of molecular testing capability in many clinical laboratories, particularly non-377 academic medical centers, was and remains a significant challenge. Early in the pandemic the 378 only tests available had to be performed in lab spaces approved for high complexity testing. 379

Unfortunately, many clinical laboratories lack that level of infrastructure and expertise. This 380 shifted the testing demand to reference laboratories, which quickly became overwhelmed 381 themselves. It was not uncommon to hear about testing delays of up to 10 days from time of 382 collection. As commercial kits were granted EUA by the FDA, the dependency on reference 383 laboratories shifted to dependency on diagnostic companies that offer moderately complexed 384 testing kits (i.e. sample-to-answer molecular tests) that do not require external extraction step 385 and molecular expertise. 386

The availability of rapid, point-of-care and at-home testing also highlighted one of the 387 major challenges of the pandemic, namely the staffing of high-complexity laboratories with 388 skilled technologists to run molecular testing. The shortage of qualified staff preceded the 389 pandemic but the problem was greatly exacerbated by the stresses placed upon the laboratory 390 by the massive testing demand. Many clinical laboratories resorted to collaboration with their 391 research counterparts to find the necessary people with appropriate skills for performing 392 molecular clinical testing. This also required that licensing be suspended in many places for the 393 duration of the pandemic. While the COVID-19 pandemic is still ongoing, efforts to anticipate 394 futures challenges will need to consider how solutions implemented during this pandemic to 395 manage staffing and supply shortages can be readily reactivated when the next pandemic hits. Early recognition of the critical role of the clinical laboratories in combating a pandemic is 420

needed. An approach akin to the Laboratory Response Network (LRN) for detection of biological 421

terrorism that includes clinical laboratories as sentinel laboratories for early detection of the pathogen of interests may be considered. Standardization from the CDC level to all public 423 health laboratories regardless of States or regions to offer early support to clinical laboratories 424 can also help mitigate some of the issues encountered during this pandemic. This would include 425 providing specimens or standards to accelerate the validation and implementation of the 426 molecular test. The COVID-19 pandemic has taught us that there is no success in being siloed. 

High-Throughput Transcription-mediated amplification on the Hologic Panther is a 619 highly sensitive method of detection for SARS-CoV-2

Evaluation of Abbott BinaxNOW Rapid Antigen 629

Test for SARS-CoV-2 Infection at Two Community-Based Testing Sites -Pima County

Performance and Implementation Evaluation of the Abbott 634

BinaxNOW Rapid Antigen Test in a High-Throughput Drive-Through Community Testing 635 Site in Massachusetts

Evaluation of three rapid lateral flow antigen detection 638 tests for the diagnosis of SARS-CoV-2 infection

A Real-World Comparison of SARS-CoV-2 Rapid 640

Antigen Testing versus PCR Testing in Florida

Loeb 68. Storch GA. 2000. Diagnostic virology

Strand-Specific Reverse Transcription PCR for Detection of 661

Replicating SARS-CoV-2

SARS-CoV-2 Virus Culture and 664

Subgenomic RNA for Respiratory Specimens from Patients with Mild Coronavirus 665

Increased viral variants in children 670 and young adults with impaired humoral immunity and persistent SARS-CoV-2 infection: 671 A consecutive case series

SARS-CoV-2 genomic and subgenomic 673

RNAs in diagnostic samples are not an indicator of active replication